Mogrosides for Delayed-Onset Muscle Soreness

NCT07836985 | Not Yet Recruiting

• 1 other identifier: GXNU20260903003
• Study Type: interventional
• Target: 16
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study will examine whether taking mogrosides, natural compounds found in monk fruit, affects delayed-onset muscle soreness (DOMS) and related markers of muscle damage, inflammation, oxidative stress, and muscle function after strenuous exercise. The study will also explore whether changes in the body's antioxidant capacity are related to changes in DOMS-related measures. The study plans to enroll 16 healthy young male students. Participants will be randomly assigned to a control group (n=8) or an experimental group (n=8). The control group will receive a placebo, and the experimental group will receive mogrosides. Participants will take their assigned product by mouth for 27 days, perform a standardized frog-jump training session, and then continue taking the assigned product for 3 more days. Researchers will measure subjective muscle soreness using a visual analog scale (VAS) at baseline before supplementation, before exercise, immediately after exercise, and 24, 48, and 72 hours after exercise. At these same time points, they will also measure serum creatine kinase (CK) and creatine kinase isoenzyme MM (CK-MM) activity, total antioxidant capacity (T-AOC), malondialdehyde (MDA), plasma interleukin-6 (IL-6), thigh circumference at the junction of the middle and lower thirds of the thigh, maximal isometric strength for lifting the thigh, and active range of motion (AROM) of the knee. The study will assess the effects of mogroside supplementation on DOMS severity and on changes in muscle damage, inflammation, oxidative stress, and muscle function. It will also explore whether improved antioxidant capacity is related to changes in DOMS-related indicators. This study is not yet recruiting participants.

Conditions

Delayed-Onset Muscle Soreness (DOMS)

Keywords

Delayed-onset muscle soreness

Outcome Measures

Primary Outcomes (1)

• Muscle Soreness Assessed by Visual Analog Scale (VAS)

  Subjective muscle soreness will be assessed at six time points: before the first dose of study product, before exercise, immediately after exercise, and 24, 48, and 72 hours after exercise. A 10-cm VAS ruler will be used. The side facing the participant is marked 0 at one end ("no pain") and 10 at the other ("worst imaginable pain"). Participants will move a cursor to indicate their current level of muscle soreness. The distance from the "no pain" end to the mark will be recorded as the pain score in centimeters. Higher scores indicate greater muscle soreness.

  From enrollment to the end of treatment at 30 days

Secondary Outcomes (3)

• Active Range of Motion (AROM) of the Knee

  From enrollment to the end of treatment at 30 days

• Maximal Isometric Muscle Force for Lifting the Thigh

  From enrollment to the end of treatment at 30 days

• Thigh Circumference at the Junction of the Middle and Lower Thirds

  From enrollment to the end of treatment at 30 days

Study Arms (2)

Mogroside

EXPERIMENTAL

Eight participants will be randomly assigned to the experimental arm. They will receive oral mogroside (batch no. YTC19011823; purity \>95%; mogroside V 50.56%), prepared as a 3% (g/mL) solution in warm drinking water, at 6 g per dose twice daily (12 g/day) in the morning and evening for 27 days. After 27 days, participants will perform a standardized frog-jump exercise to induce delayed-onset muscle soreness (DOMS): 10 sets of 25 consecutive jumps, with 2 minutes of rest between sets, after a 10-minute warm-up; total session approximately 34-35 minutes. They will continue the same mogroside intervention for 3 additional days after exercise. All participants will complete the same scheduled assessments. The study will be double-blind.

Drug: Mogroside

Placebo

PLACEBO COMPARATOR

Eight participants will be randomly assigned to the control arm. They will receive an equal volume of warm drinking water as placebo twice daily in the morning and evening for 27 days. After 27 days, participants will perform the same standardized frog-jump exercise to induce delayed-onset muscle soreness (DOMS): 10 sets of 25 consecutive jumps, with 2 minutes of rest between sets, after a 10-minute warm-up; total session approximately 34-35 minutes. They will continue the same placebo intervention for 3 additional days after exercise. All participants will complete the same scheduled assessments. The study will be double-blind.

Other: Placebo

Interventions

Mogroside DRUG

Eight participants will be randomly assigned to the experimental arm. They will receive oral mogroside (batch no. YTC19011823; purity \>95%; mogroside V 50.56%), prepared as a 3% (g/mL) solution in warm drinking water, at 6 g per dose twice daily (12 g/day) in the morning and evening for 27 days. After 27 days, participants will perform a standardized frog-jump exercise to induce delayed-onset muscle soreness (DOMS): 10 sets of 25 consecutive jumps, with 2 minutes of rest between sets, after a 10-minute warm-up; total session approximately 34-35 minutes. They will continue the same mogroside intervention for 3 additional days after exercise. All participants will complete the same scheduled assessments. The study will be double-blind.

Mogroside

Placebo OTHER

Eight participants will be randomly assigned to the control arm. They will receive an equal volume of warm drinking water as placebo twice daily in the morning and evening for 27 days. After 27 days, participants will perform the same standardized frog-jump exercise to induce delayed-onset muscle soreness (DOMS): 10 sets of 25 consecutive jumps, with 2 minutes of rest between sets, after a 10-minute warm-up; total session approximately 34-35 minutes. They will continue the same placebo intervention for 3 additional days after exercise. All participants will complete the same scheduled assessments. The study will be double-blind.

Placebo

Eligibility Criteria

• Age: 20 Years - 23 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Male, aged 20 to 23 years.
• Healthy, with no history of major diseases or severe injuries.
• Physical fitness level comparable to that of an ordinary physical education/sports student.
• No training or competition obligations during the study period.
• Provides informed consent for the study protocol.

You may not qualify if:

• History of musculoskeletal injury within the past 2 months.
• Use of anti-inflammatory drugs or steroid medications within the past 1 month.
• Use of antioxidant medications such as vitamin E or vitamin C within the past 1 month.
• Use of any other medications within the past 2 weeks.
• Participation in strenuous exercise within the past 10 days.

Sponsors & Collaborators

• Guangxi Normal University: lead

Central Study Contacts

Jingzhi Zhang

CONTACT

+86 16677137704; 170787717@qq.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Guangxi Normal University

Study Record Dates

• First Submitted: September 17, 2026
• First Posted: September 23, 2026
• Study Start: September 19, 2026
• Primary Completion (Estimated): November 1, 2026
• Study Completion (Estimated): November 1, 2026
• Last Updated: September 23, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share